Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

NYU Langone Health27 enrolled

Overview

Aging is the primary risk factor in aging-related dementia. An important initiating factor for the development and progression of cognitive impairment is disruption of the blood-brain barrier (BBB). BBB plays an important role in maintaining normal brain homeostasis and protecting neural tissues from toxins. It is hypothesized that such changes known to be common in aging and can be an early process that precedes Alzheimer's Disease (AD). The microvascular changes related to subtle BBB disruption can be measured with permeability-surface area (PS) derived from GRASP DCE-MRI acquired less than 10 minutes, and the patterns of increased PS in normal and abnormal aging are different.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Alzheimer Disease

Interventions

GRASP Dynamic Contrast-Enhanced (DCE) MRIDEVICE

Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.

Gadolinium-based Contrast Agent (GBCA) for MRIDRUG

Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 85 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects that have been diagnosed with aMCI ages 65-85 Exclusion Criteria: * Pregnant, planning to get pregnant, or nursing. * Claustrophobia * Cardiac pacemaker * Intracranial clips, metal implants, unremovable jewelries, metal in eyes. * History or presence of any other major medical, neurologic or psychiatric conditions, such as Alzheimer's diseases, Parkinson's diseases, and stroke. * Renal or liver disease as this may cause concerns related to Gad-based contrast agent * Allergy to the contrast agent Gadolinium

Outcomes

Primary Outcomes

Permeability Surface Area (PS) as Measured by GRASP DCE-MRI Sequence

PS is measured by quantifying the contrast agent flow through blood vessel walls per unit volume of brain while accounting for the blood flow rate in the vessel.

Time frame: Up to 21 Minutes

Blood-Brain Barrier (BBB) Permeability as Measured by GRASP DCE-MRI Sequence

Golden-angle Radial Sparse Parallel (GRASP) dynamic contrast-enhanced (DCE) MRI sequence will be collected for the quantification of subtle BBB leakage throughout the brain.